The FDA has approved Emend for injection (fosaprepitant dimeglumine, from Merck) for the prevention of chemotherapy-induced nausea and vomiting in combination with other antiemetics. Emend for ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Fosaprepitant for Injection, the ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Fosaprepitant for Injection 150 mg per vial, the newest addition to the company’s ...
Avenacy, a specialty pharmaceutical company focused on supplying injectable medications, has launched Fosaprepitant for Injection and Fulvestrant Injection. “Avenacy has had a strong start to 2024, ...
SAN DIEGO, Feb. 26, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class ...
Co confirmed that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for the Co's New Drug Application (NDA) for EMEND (fosaprepitant dimeglumine) For Injection, ...
The association between atopy and Hodgkin’s lymphoma in teenagers and young adults: A UK nationwide case control study. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This ...
(RTTNews) - Pharmaceutical company Dr. Reddy's Laboratories Ltd. (RDY) announced Wednesday the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND (fosaprepitant) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results